Ashley Chan

New preoperative and postoperative models can help identify those at high risk of breast cancer-related lymphedema following surgery.

Skipping radiation therapy for patients with a subset of breast cancer offers them a ‘peace of mind,’ an expert stated.

The use of Gavreto is shown to be effective and very well-tolerated in patients with metastatic RET fusion-positive NSCLC, according to an expert.

Cancer survivors who consume alcohol may experience worse outcomes, as alcohol usage can interfere with treatment results.

Cancer survivors who received care plans were more likely to regularly attend cancer-related follow-up care visits, researchers found.

Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer.

Treatment with Welireg significantly improved progression-free survival rates in patients with advanced renal cell carcinoma, the most common type of kidney cancer.

Patients with primary central nervous system lymphoma aged 70 and older may be eligible for Imbruvica as maintenance treatment.

In patients with cancer, psychological distresses such as anxiety and depression are associated with slower time from receiving a diagnosis until the first session of treatment.

Patients with HER2-positive metastatic breast cancer may receive sufficient first-line treatment with Perjeta plus Herceptin without chemotherapy.

Using inter-arterial chemotherapy compared to intravenous chemotherapy may significantly improve globe salvage rates in children with advanced unilateral retinoblastoma.

There are multiple types of skin cancer and treatments to treat the disease, too, explained an expert.

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

Patients with non-small cell lung cancer who recently received surgery are more susceptible to wildfire smoke exposure, worsening their overall survival rate.

Patients with HER2-expressing cancers using Enhertu saw significant improvements in progression-free survival and overall survival.

Using Recentin (cediranib) can help stabilize disease in patients with alveolar soft-part sarcoma, a rare sarcoma subset.

Patients with a history of proton pump inhibitor use and who have NSCLC with a PD-L1 tumor proportion score of 50% or more benefit from immune checkpoint inhibitor plus chemotherapy as treatment.

Caregivers of patients with head and neck cancer tend to face severe stress and burden related to their jobs, and it’s essential to implement more work-life balance.

Chemotherapy treatment can lead to bacterial changes in the gut and unhealthy weight gain for patients, with potential higher risk of morbidity and reduced quality of life, according to recent research.

Patients with a subset of acute myeloid leukemia may have improved survival rates and lower risk of relapse with Nexavar maintenance.

Cost burdens are prevalent among patients with metastatic prostate cancer; however, utilizing appropriate resources could reduce costs up to 100%.

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.

Rivoceranib plus Airuika demonstrates improvement for survival in patients with unresectable hepatocellular carcinoma, a subset of liver cancer.

Implementing longer intervals between the completion of neoadjuvant therapy and surgery may have a positive effect on pathologic complete responses for patients with locally advanced rectal cancer.

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

Treatment time for patients with early-detected breast cancer may be reduced by one week with the use of simulated integrated boost (SIB) radiotherapy.

Patients with non-microsatellite instability-high metastatic colorectal cancer had better survival rates from the botensilimab and balstilimab combination.

Simultaneous administration of the novel oral S-1 chemotherapy and SIB-RT could improve survival rates for patients aged 70 and older with esophageal squamous cell carcinoma (ESCC).

Patients with both metastatic non-small cell lung cancer and preexisting diabetes mellitus have different outcomes depending on treatment and treatment combinations, particularly with Keytruda and chemotherapy